This algorithm has quadratic run time so it can be slow with very large profiles ... with many edges meeting at each polygon vertex. The result is an alternation of flat triangular faces with conical ...

At a time when many life sciences companies are shrinking their workforce, Vertex Pharmaceuticals Inc. has once again grown ...

For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

"If we do our jobs right, and you come back a year from now, this place is going to be a buzzing hive" -- Vertex Executive ...

Vertex Pharmaceuticals is working toward making its recently approved non-opioid pain medicine Journavx not only broadly ...

Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) ...

One of the most significant news items involving Vertex isn't reflected in the company's numbers just yet. Vertex's ...

The FDA recently approved Journavx for treating acute pain. This approval is tremendously important for Vertex Pharmaceuticals. The biotech company has also received other good news over the last ...

Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare sector as a whole. This time last year, the biotech ...

With a market cap of $118.7 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology leader specializing ...

Analyst Michael Yee of Jefferies maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of $550.00. Michael Yee’s rating is based on Vertex ...